Centogene N.V., a commercial-stage company focused on generating data-driven insights into rare diseases, has expanded its partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing treatments for genetically defined diseases.   CENTOGENE will provide genetic testing and clinical trial support for Agios’ three global, pivotal trials in thalassemia and sickle cell disease. Under a previous agreement, CENTOGENE provided support for Agios’ pyruvate kinas...